Intercell Files Application With EMEA

Austrian drug company Intercell has submitted a marketing authorization application for its vaccine against Japanese encephalitis.

Following Phase III trials in Europe, the U.S. and Australia, the new vaccine will be licensed through the centralized regulatory procedure by the European Medicines Agency (EMEA).

Thomas Lingelbach, Intercell’s chief operating officer, said the company intends to file a license application in the U.S. by the end of the year.